The European healthcare technology sector experienced a major market reaction after Danish audio technology company GN Store Nord announced an agreement to sell its hearing aid division to Italian hearing care retailer Amplifon. Equity analysts at BUCKSA analyze how this significant transaction could reshape competition within the global hearing care industry.
Following the announcement, GN Store Nord shares surged approximately 36%, reflecting strong market approval of the company’s decision to divest its hearing aid operations. In contrast, Amplifon shares declined more than 8%, as markets evaluated the financial implications of the acquisition and the increased leverage required to finance the deal.
The transaction places a valuation of roughly DKK17 billion on GN’s hearing division, making it one of the largest strategic transactions in the hearing technology sector in recent years.
Deal Structure And Financial Consideration
Under the agreement, Amplifon will pay approximately DKK12.6 billion in cash, while the remaining value will be settled through the issuance of roughly 56 million Amplifon shares.
After the transaction closes, GN Store Nord will hold approximately 16% of Amplifon’s outstanding share capital, although the stake will be subject to lock up restrictions that prevent immediate share sales.
This structure allows GN Store Nord to strengthen its balance sheet, reduce debt exposure, and still retain participation in the long term development of the hearing care market through its equity stake in Amplifon.
Following completion of the deal, Amplifon’s leverage ratio is expected to reach roughly 3 times pro forma earnings, reflecting the additional borrowing required to finance the acquisition.
Strategic Impact On The Hearing Care Market
The acquisition is expected to create a significantly larger hearing care group with estimated combined revenue of approximately €3.3 billion and pro forma adjusted EBITDA of about €830 million.
Analysts estimate operational synergies could generate between €60 million and €80 million in annual benefits by the end of 2029, while integration costs are projected to reach roughly €80 million during the first two to three years following completion.
The deal also transforms Amplifon’s operating structure. Previously known primarily as a global hearing aid retailer, the company will now gain direct manufacturing capabilities, creating a vertically integrated hearing technology business.
This strategic shift positions Amplifon alongside competitors that combine product manufacturing, supply chains, and global retail distribution networks within a single corporate structure.
Financial Performance Of The Hearing Division
The business unit being sold generated revenue of approximately DKK7.21 billion in 2025 and delivered pro forma EBITDA of roughly DKK1.19 billion.
The division includes several well known hearing technology brands, including ReSound and Beltone, along with their associated intellectual property, research and development programs, manufacturing facilities, and global distribution partnerships.
For Amplifon, acquiring these assets significantly expands its role within the hearing technology ecosystem by providing greater control over product development, manufacturing capacity, and global supply networks.
Company leadership described the acquisition as the most transformative transaction in Amplifon’s 75 year corporate history.
GN Store Nord Strategic Refocusing
For GN Store Nord, the transaction represents a major shift in corporate strategy.
The divestiture allows the company to reduce financial leverage, which previously exceeded 4 times earnings at the end of 2025, while enabling management to concentrate resources on its remaining technology divisions.
These divisions include enterprise communication technologies and gaming audio products, both expected to serve as the company’s primary long term growth drivers.
The company also revised its 2026 organic revenue growth guidance to between 2% and 8%, reflecting the expected performance of its remaining operations following the sale.
At the same time, GN Store Nord suspended its long term financial targets, allowing management to reassess strategic priorities after the divestiture.
Transaction Timeline And Regulatory Process
Completion of the transaction is expected by the end of 2026, although several regulatory approvals must still be obtained before the acquisition becomes final.
The agreement requires merger control approval from regulatory authorities and the completion of a statutory demerger under the Danish Companies Act, which will separate the hearing division from GN Store Nord prior to its transfer to Amplifon.
Both companies have expressed confidence that the regulatory review process will proceed according to schedule.
Broader Implications For The Hearing Technology Industry
The agreement between GN Store Nord and Amplifon, valued at DKK17 billion, highlights the increasing importance of scale, manufacturing control, and vertically integrated supply chains within the global hearing technology sector.
As demand for hearing solutions continues to rise due to aging populations and expanding healthcare access, companies across the industry are seeking ways to strengthen technological capabilities and global distribution networks.
Combining Amplifon’s retail infrastructure with GN Store Nord’s manufacturing expertise may create a stronger competitive entity capable of challenging other integrated hearing care groups operating worldwide.
